MAM
CSTL icon

Meeder Asset Management’s Castle Biosciences CSTL Stock Holding History

Meeder Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.5K Buy
+387
New +$12.7K ﹤0.01% 706
2020
Q4 		– Sell
-1,294
Closed -$66K – 1949
2020
Q3 		$66K Buy
+1,294
New +$57.6K ﹤0.01% 897

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's CSTL Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Castle Biosciences (CSTL) in Q1 2026: 387 shares worth $9.5K. The stake represents ﹤0.01% of the portfolio and ranks #706 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in CSTL as recently as Q3 2020.

Meeder Asset Management first reported a position in CSTL in Q3 2020 and has held it in 2 quarters since. The position peaked at $66K in Q3 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Meeder Asset Management held 387 shares of Castle Biosciences worth $9.5K as of Q1 2026.
  • Castle Biosciences was a new Meeder Asset Management position in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #706 holding.
  • Meeder Asset Management first reported a position in Castle Biosciences in Q3 2020 and has held it in 2 quarters since.
  • Meeder Asset Management's Castle Biosciences position peaked at $66K in Q3 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.